{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063735","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.452624+00:00","generated_at":"2026-06-08T03:54:45.950319+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tivic Health Q3 revenue down 41% YoY to $282K; gross profit up 71% to $108K","bullets":["Net loss of $1.8M narrowed from $2.6M in Q3 2022; operating expenses fell 30% to $1.9M.","Gross margin improved to 38% from 13% YoY on price increases and supply-chain optimization.","Cash and equivalents totaled $5.2M as of Sept 30, 2023.","Announced partnerships with InStep Health and Amerisource Bergen; NASDAQ compliance regained after reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063735","json":"https://secwatch.observer/filing/0000950170-23-063735.json","markdown":"https://secwatch.observer/filing/0000950170-23-063735.md","text":"https://secwatch.observer/filing/0000950170-23-063735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/0000950170-23-063735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/tivc-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:54:45.950319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dacbc50db30343c2811bcc504ad99647d1e171dd","claim":"Valion Bio, Inc. reported the third quarter 2023 ended September 30, 2023 results: revenue $282 thousand.","evidence_excerpt":"medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”). Third Quarter 2023 Financial Highlights • Revenue for Q3 2023 was $282 thousand, compared to $161 thousand for Q2 2023 and $477 thousand in Q3 2022. • Gross profit was $108 thousand, compared to $63 thousand in Q3 2022, an increase of 71%. • Gross Margin of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/0000950170-23-063735-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2023 ended September 30, 2023"},{"label":"Revenue","value":"$282 thousand"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}